Medscape is available in 5 Language Editions – Choose your Edition here.


Postoperative Corneal Melt Treatment & Management

  • Author: Arun Verma, MD; Chief Editor: Hampton Roy, Sr, MD  more...
Updated: Dec 01, 2015

Medical Care

Corneal melting, a condition that may lead to corneal perforation (open injury), is often an indication of a systemic disease, such as rheumatoid arthritis or lupus, and, therefore, requires systemic treatment rather than just topical eye drop application. It is extremely important that patients be treated by an expert physician who specializes and understands the process of eye melt, which can be a presenting sign of serious systemic disorder that can benefit dramatically with systemic treatment. The team of physicians and ophthalmologists should be experts at providing ocular and systemic care to patients with such disorders. Drugs used in the treatment of these eye diseases can have significant adverse effects, including bone marrow suppression, and improper use or dosages can be devastating. However, the corneal melt itself can be equally devastating to one’s vision, potentially leading to perforation of the cornea and/or loss of vision. Therefore, the risks and benefits are heavily weighed, andaninformed decision is made as to the best course of treatment.

Patients who initially present with punctate corneal staining that becomes an epithelial defect may ultimately develop stromal loss. Most of these patients do not complain of pain.

Yang and Kline reported 5 cases of stromal loss among approximately 600 patients, which is an incidence rate of 0.01%.[6] Gelender reported 5 cases of stromal loss, and Insler and colleagues reported 4 cases.[7, 8] All of the patients described by Yang and Kline as well as by Insler and colleagues had associated collagen vascular disease.[6, 8] All but one of these patients had rheumatoid arthritis; the other patient had scleroderma. In Gelender's initial report, only one patient had Stevens-Johnson disease; the other patients were apparently healthy.[7] The findings from the studies performed to detect collagen vascular diseases after the ulcer was detected were negative. More recently, several cases believed to be secondary to the extended use of topical nonsteroidal anti-inflammatory drugs (NSAIDs) have been reported.

Acute bacterial, viral, or fungal ulcers usually produce a prominent inflammatory reaction, often with a hypopyon, while eyes with corneal melting appear quieter. Postoperatively, if a surgeon discovers a corneal ulcer in a patient, the ulcer should be cultured. Eye drops that are toxic to the epithelium (eg, steroids, NSAIDs, antibiotics, beta-blockers, epinephrine) should be discontinued.

If the eye is relatively quiet and the problem appears to be a corneal melt rather than an infectious corneal ulcer, frequent lubrication with a nonpreserved drop or ointment should be instituted, and the patient should be monitored closely, particularly if a descemetocele seems imminent. Hospitalization may be necessary. Bandage contact lenses may also be of value, but the patient should be monitored closely because a secondary bacterial ulcer may develop.

Corneal cyanoacrylate gluing is recommended if the cornea appears to be progressively thinning. Healing results in approximately 60% of cases. Spontaneous perforation should be treated with either a lamellar keratoplasty or a penetrating keratoplasty.[9] Gelender reported that a conjunctival flap helps stabilize the cornea.[7] Tarsorrhaphy and punctal occlusion may also be considered. The proteases produced by PMNs and diseased epithelium may contribute to corneal melting. The eye should be treated with nonpreserved lubricating ointments combined with taping the lid shut or tarsorrhaphy unless the eye is inflamed.

Keratoconjunctivitis sicca always should be ruled out and treated appropriately when corneal disease is associated with rheumatoid arthritis because sterile corneal ulceration and melting may be associated with dry eyes. Corneal involvement in rheumatoid arthritis includes keratitis, sclerosing keratitis, keratolysis, and peripheral corneal melting. The marginal corneal ulceration may involve the entire circumference in the limbal area, or it may be in a localized zone and frequently is accompanied by significant pain. Marginal corneal ulceration may be quiet and asymptomatic in other patients, and it occurs with or without associated scleral or episcleral inflammation.

Adequate lubrication with preservative-free tear and ointment supplements is very important. Acetylcysteine (Mucomyst 10-20%), used 4-6 times daily, is a topical collagenase inhibitor that may be beneficial in some patients. Topical high-dose corticosteroids may relieve associated scleritis and prevent progression of ulcerative keratitis. In certain cases, especially in patients with dry eye, topical corticosteroids can enhance melting. Later in the disease process, medroxyprogesterone acetate 1% may be used as a topical anti-inflammatory agent that does not inhibit collagen synthesis. If melting is progressive, a hydrophilic bandage contact lens may be helpful in promoting epithelial resurfacing; in thin corneas with impending perforation, a tissue adhesive may be applied. If the above treatment is ineffective, a 3-5 mm resection of the conjunctiva adjacent to the furrow itself may be performed. Systemic immunosuppression is the definitive therapy.

The use of collagenase inhibitors as adjunctive therapy in the treatment of progressive corneal melting has been disappointing. Both disodium edetic acid and acetylcysteine have been used to inhibit collagenase activity, particularly in Pseudomonas corneal infections. Additional enzyme inhibitors, such as the metalloproteinases, are under investigation and may be of clinical value in the future. The rationale for their use is to prevent corneal tissue destruction, but there has been no clear evidence that they have been of clinical benefit.

Corticosteroids also can predispose to secondary complications, including microbial superinfection, stromal melting, secondary glaucoma, and cataract formation. Once corticosteroids are begun, it often is difficult to discontinue them, and a marked rebound inflammatory response can ensue with a withdrawal that is too abrupt. Patients should be forewarned of the potential for chronic topical corticosteroid treatment, even at low doses. Steroids should not be used in cases of exposure or neurotrophic keratitis because of the possibility of keratolysis.

People have underscored the prophylactic benefit of early, large tarsorrhaphy to prevent initial epithelial erosion with subsequent corneal melting and perforation. Therapeutic soft contact lenses may be a reasonable short-term strategy.

Impending or actual corneal perforation, if less than 1.5 mm in diameter, can be treated successfully with 2-butyl-cyanoacrylate (Histoacryl) adhesive and a therapeutic soft contact lens (eg, Bausch & Lomb plano T). Larger perforations should be treated immediately with scleral or corneal patch grafting. These grafts may need to be covered with conjunctiva (or amniotic membrane) to prevent the same melting process from destroying the scleral or corneal patch graft. Topical steroid therapy should be tapered, and cycloplegics should be added in concert with corneal gluing.

Clinical and basic research continues to explore how stem cell functions can be modulated by soluble cytokines and how insoluble matrix autologous serum eye drops (frequent preservative-free artificial tears, highly viscous methyl cellulose) probably help promote epithelial healing. A high rate of immune reactions can be expected because of the high immunogenic stimulus of the limbal transplant related to relative abundance of Langerhans cells and human leukocyte antigen DR (HLA-DR) antigens. Effective immunosuppression is considered essential.

Oral cyclosporin A and topical cyclosporin A (0.05%) can be used in melting stromal ulcers. It may be a good alternative mode of achieving ocular immunosuppression.


Surgical Care

Single dose application of topical mitomycin can be associated with serious complication (ie, corneal melting leading to perforation). The patient can be treated with lamellar corneal transplant. Epithelial ingrowth may develop in the lamellar interface after LASIK and may be associated with melting of the edge of the flap. This undesirable complication can be treated successfully with early surgical removal of the epithelium and proper reattachment of the flap.


Prompt initiation of therapy directed at the specific cause is required to promote epithelial healing. Conjunctival flaps play a less important role in the treatment of perforations than they do in the prevention of progression of corneal melting. Nonetheless, in some leaking descemetoceles and small perforations, conjunctival flaps may serve as a temporizing measure before keratoplasty. However, with the use of tissue adhesives and patch grafting, the use of conjunctival flaps for perforation has become almost obsolete.

Partial-thickness scleral flaps may be dissected with a base at the limbus and then reflected onto the cornea and sutured in place to treat small peripheral corneal perforations. To be most effective, the epithelium and the necrotic material surrounding the leak must be removed, and dissection of a small lamellar bed is helpful in suturing the sclera to the cornea. This technique is cosmetically less acceptable than the use of corneal material but may be of value in emergency situations.

Another technique using autologous cornea has been described in which a small trephine (2 mm) was used to dissect a half-thickness peripheral corneal button, which was sutured in place over a perforation in the cornea of the same eye. The donor site healed without complication, and the perforation was repaired. The most frequently used techniques for definitive repair of perforations involve some form of keratoplasty using donor material. The choice between lamellar and full-thickness penetrating keratoplasty depends on a number of factors, including location and size of the perforation, donor tissue availability, and associated ocular findings. It is better to choose lamellar grafting when the perforation is small and peripheral. Also, when marked anterior segment inflammation and a formed chamber are present, lamellar patch grafting may avoid instrumentation of the anterior chamber and the risk of fibrin outpouring, chamber flattening, and formation of synechiae.

Lamellar keratoplasty depends on the same principles as the use of tissue adhesive, ie, debridement of necrotic material and removal of surrounding epithelium. Additionally, a clean edge for suture placement is necessary and a dry bed is not necessary.

Penetrating keratoplasty for corneal perforation is the most aggressive approach but also may be mandated by the circumstances present. Large perforations, too large to seal with tissue adhesives or lamellar patch grafting, and smaller perforations surrounded by large areas of tissue necrosis may need penetrating grafts. The technique is that of standard penetrating keratoplasty with modifications because of the softness of the eye. With smaller perforations, tissue adhesives may be used to temporarily plug the leak, so that trephination may be performed. Viscoelastics may be used to help form the anterior chamber by injection through the perforation site. Either way, a trephine large enough to surround all the necrotic tissue should be used. A donor cornea that is 0.50 mm larger, then is sutured in place.



An internist or rheumatologist may be consulted if a systemic disease is believed to cause the melting.

Contributor Information and Disclosures

Arun Verma, MD Senior Consultant, Department of Ophthalmology, Dr Daljit Singh Eye Hospital, India

Disclosure: Nothing to disclose.

Specialty Editor Board

Francisco Talavera, PharmD, PhD Adjunct Assistant Professor, University of Nebraska Medical Center College of Pharmacy; Editor-in-Chief, Medscape Drug Reference

Disclosure: Received salary from Medscape for employment. for: Medscape.

Christopher J Rapuano, MD Professor, Department of Ophthalmology, Jefferson Medical College of Thomas Jefferson University; Director of the Cornea Service, Co-Director of Refractive Surgery Department, Wills Eye Hospital

Christopher J Rapuano, MD is a member of the following medical societies: American Academy of Ophthalmology, American Ophthalmological Society, American Society of Cataract and Refractive Surgery, Contact Lens Association of Ophthalmologists, International Society of Refractive Surgery, Cornea Society, Eye Bank Association of America

Disclosure: Serve(d) as a director, officer, partner, employee, advisor, consultant or trustee for: Cornea Society, Allergan, Bausch & Lomb, Bio-Tissue, Shire, TearScience, TearLab<br/>Serve(d) as a speaker or a member of a speakers bureau for: Allergan, Bausch & Lomb, Bio-Tissue, TearScience.

Chief Editor

Hampton Roy, Sr, MD Associate Clinical Professor, Department of Ophthalmology, University of Arkansas for Medical Sciences

Hampton Roy, Sr, MD is a member of the following medical societies: American Academy of Ophthalmology, American College of Surgeons, Pan-American Association of Ophthalmology

Disclosure: Nothing to disclose.

Additional Contributors

Richard W Allinson, MD Associate Professor, Department of Ophthalmology, Texas A&M University Health Science Center; Senior Staff Ophthalmologist, Scott and White Clinic

Richard W Allinson, MD is a member of the following medical societies: American Academy of Ophthalmology, American Medical Association, Texas Medical Association

Disclosure: Nothing to disclose.

  1. Cottinger, AJ, Berkley, RP, Nordan IT, et al. Bacterial corneal ulcers following keratorefractive surgery. A retrospective study of 14163 procedures. Paper presented at: Ocular Microbiology Immunology Group Meeting. San Francisco, CA; September 28, 1985.

  2. Kymionis GD, Kankariya VP, Kontadakis GA. Combined treatment with flap amputation, phototherapeutic keratectomy, and collagen crosslinking in severe intractable post-LASIK atypical mycobacterial infection with corneal melt. J Cataract Refract Surg. 2012 Apr. 38(4):713-5. [Medline].

  3. Greiner MA, Li JY, Mannis MJ. Longer-term vision outcomes and complications with the Boston type 1 keratoprosthesis at the University of California, Davis. Ophthalmology. 2011 Aug. 118(8):1543-50. [Medline].

  4. Sivaraman KR, Hou JH, Allemann N, de la Cruz J, Cortina MS. Retroprosthetic membrane and risk of sterile keratolysis in patients with type I Boston Keratoprosthesis. Am J Ophthalmol. 2013 May. 155(5):814-22. [Medline].

  5. Praidou A, Brazitikos P, Dastiridou A, Androudi S. Severe unilateral corneal melting after uneventful phacoemulsification cataract surgery. Clin Exp Optom. 2013 Jan. 96(1):109-11. [Medline].

  6. Yang HK, Kline OR Jr. Corneal melting with intraocular lenses. Arch Ophthalmol. 1982 Aug. 100(8):1272-4. [Medline].

  7. Gelender H. Descemetocele after intraocular lens implantation. Arch Ophthalmol. 1982 Jan. 100(1):72-6. [Medline].

  8. Insler MS, Boutros G, Boulware DW. Corneal ulceration following cataract surgery in patients with rheumatoid arthritis. J Am Intraocul Implant Soc. 1985 Nov. 11(6):594-7. [Medline].

  9. Utine CA, Tzu JH, Akpek EK. Lamellar keratoplasty using gamma-irradiated corneal lenticules. Am J Ophthalmol. 2011 Jan. 151(1):170-174.e1. [Medline].

  10. Barletta JP, Angella G, Balch KC, Dimova HG, Stern GA, Moser MT, et al. Inhibition of pseudomonal ulceration in rabbit corneas by a synthetic matrix metalloproteinase inhibitor. Invest Ophthalmol Vis Sci. 1996 Jan. 37(1):20-8. [Medline].

  11. Barletta JP, Balch KC, Dimova, et al. Inhibition of Pseudomonas corneal ulcers by a synthetic matrix metalloprotease inhibitor Galardin (GM[6001]). Invest Ophthalmol Vis Sci. 1993. 34:1058.

  12. Benson WE, Diamond JG, Tasman W. Intraocular irrigating solutions for pars plana vitrectomy. A prospective, randomized, double-blind study. Arch Ophthalmol. 1981 Jun. 99(6):1013-5. [Medline].

  13. Bernauer W, Ficker LA, Watson PG, Dart JK. The management of corneal perforations associated with rheumatoid arthritis. An analysis of 32 eyes. Ophthalmology. 1995 Sep. 102(9):1325-37. [Medline].

  14. Binder PS, Baumgartner SD, Fogle JA. Histopathology of a case of epikeratophakia (aphakic epikeratoplasty). Arch Ophthalmol. 1985 Sep. 103(9):1357-63. [Medline].

  15. Binder PS, Zavala EY. Why do some epikeratoplasties fail?. Arch Ophthalmol. 1987 Jan. 105(1):63-9. [Medline].

  16. Cameron ME. Preventable complications of pterygium excision with beta-irradiation. Br J Ophthalmol. 1972 Jan. 56(1):52-6. [Medline].

  17. Castillo A, Diaz-Valle D, Gutierrez AR, Toledano N, Romero F. Peripheral melt of flap after laser in situ keratomileusis. J Refract Surg. 1998 Jan-Feb. 14(1):61-3. [Medline].

  18. Chung H, Tolentino FI, Cajita VN, Acosta J, Refojo MF. Reevaluation of corneal complications after closed vitrectomy. Arch Ophthalmol. 1988 Jul. 106(7):916-9. [Medline].

  19. Clewes AR, Tunn EJ, Kaye S, Bucknall RC. Use of intravenous cyclophosphamide in the prevention of corneal melt: justified or not?. Rheumatology (Oxford). 2005 Feb. 44(2):257-8. [Medline].

  20. Dougherty PJ, Hardten DR, Lindstrom RL. Corneoscleral melt after pterygium surgery using a single intraoperative application of mitomycin-C. Cornea. 1996 Sep. 15(5):537-40. [Medline].

  21. Dua HS, Saini JS, Azuara-Blanco A, Gupta P. Limbal stem cell deficiency: concept, aetiology, clinical presentation, diagnosis and management. Indian J Ophthalmol. 2000 Jun. 48(2):83-92. [Medline].

  22. Edelhauser HF, Hine JE, Pederson H, Van Horn DL, Schultz RO. The effect of phenylephrine on the cornea. Arch Ophthalmol. 1979 May. 97(5):937-47. [Medline].

  23. Ewing-Chow DA, Romanchuk KG, Gilmour GR, Underhill JH, Climenhaga DB. Corneal melting after pterygium removal followed by topical mitomycin C therapy. Can J Ophthalmol. 1992 Jun. 27(4):197-9. [Medline].

  24. Farrell PL, Smith RE. Bacterial corneoscleritis complicating pterygium excision. Am J Ophthalmol. 1989 May 15. 107(5):515-7. [Medline].

  25. Foulks GN, Thoft RA, Perry HD, Tolentino FI. Factors related to corneal epithelial complications after closed vitrectomy in diabetics. Arch Ophthalmol. 1979 Jun. 97(6):1076-8. [Medline].

  26. Gelender H. Corneal melting syndrome. Arch Ophthalmol. 1983 Feb. 101(2):303. [Medline].

  27. Gilliland GD, Hutton WL, Fuller DG. Retained intravitreal lens fragments after cataract surgery. Ophthalmology. 1992 Aug. 99(8):1263-7; discussion 1268-9. [Medline].

  28. Grayson, M. Diseases of the Cornea. 2nd ed. St Louis: CV Mosby; 1983.

  29. Gupta S, Basti S. Corneoscleral, ciliary body, and vitreoretinal toxicity after excessive instillation of mitomycin C. Am J Ophthalmol. 1992 Oct 15. 114(4):503-4. [Medline].

  30. Hoffer KJ, Darin JJ, Pettit TH, Hofbauer JD, Elander R, Levenson JE. Three years experience with radial keratotomy. The UCLA study. Ophthalmology. 1983 Jun. 90(6):627-36. [Medline].

  31. Hong C, Kitazawa Y, Tanishima T. Influence of argon laser treatment of glaucoma on corneal endothelium. Jpn J Ophthalmol. 1983. 27(4):567-74. [Medline].

  32. Lam DS, Leung AT, Wu JT, Fan DS, Cheng AC, Wang Z. Culture-negative ulcerative keratitis after laser in situ keratomileusis. J Cataract Refract Surg. 1999 Jul. 25(7):1004-8. [Medline].

  33. Latina MA, Melamed S, March WF, Kass MA, Kolker AE. Gonioscopic ab interno laser sclerostomy. A pilot study in glaucoma patients. Ophthalmology. 1992 Nov. 99(11):1736-44. [Medline].

  34. Leahey AB, Gottsch JD, Stark WJ. Clinical experience with N-butyl cyanoacrylate (Nexacryl) tissue adhesive. Ophthalmology. 1993 Feb. 100(2):173-80. [Medline].

  35. Lemp MA. Cornea and sclera. Arch Ophthalmol. 1974 Aug. 92(2):158-70. [Medline].

  36. Liu SM, Su J, Hemady RK. Corneal melting after avulsion of a Molteno shunt plate. J Glaucoma. 1997 Dec. 6(6):357-8. [Medline].

  37. Mamalis N, Johnson MD, Haines JM, Teske MP, Olson RJ. Corneal-scleral melt in association with cataract surgery and intraocular lenses: a report of four cases. J Cataract Refract Surg. 1990 Jan. 16(1):108-15. [Medline].

  38. Mandelbaum S, Waring GO 3rd, Forster RK, Culbertson WW, Rowsey JJ, Espinal ME. Late development of ulcerative keratitis in radial keratotomy scars. Arch Ophthalmol. 1986 Aug. 104(8):1156-60. [Medline].

  39. Margherio RR, Cox MS Jr, Trese MT, Murphy PL, Johnson J, Minor LA. Removal of epimacular membranes. Ophthalmology. 1985 Aug. 92(8):1075-83. [Medline].

  40. Margo CE, Polack FM, Hood CI. Aspergillus panophthalmitis complicating treatment of pterygium. Cornea. 1988. 7(4):285-9. [Medline].

  41. Morgan KS, Asbell PA, McDonald MB, May JG, Loupe DN, Kaufman HE. Preliminary visual results of pediatric epikeratophakia. Arch Ophthalmol. 1983 Oct. 101(10):1540-4. [Medline].

  42. Nelson JD, Williams P, Lindstrom RL, Doughman DJ. Map-fingerprint-dot changes in the corneal epithelial basement membrane following radial keratotomy. Ophthalmology. 1985 Feb. 92(2):199-205. [Medline].

  43. Ohashi Y, Matsuda M, Hosotani H, Tano Y, Ishimoto I, Fukuda M, et al. Aldose reductase inhibitor (CT-112) eyedrops for diabetic corneal epitheliopathy. Am J Ophthalmol. 1988 Mar 15. 105(3):233-8. [Medline].

  44. Pflugfelder SC, Saulson R, Ullman S. Peripheral corneal ulceration in a patient with AIDS-related complex. Am J Ophthalmol. 1987 Nov 15. 104(5):542-3. [Medline].

  45. Portnoy SL, Insler MS, Kaufman HE. Surgical management of corneal ulceration and perforation. Surv Ophthalmol. 1989 Jul-Aug. 34(1):47-58. [Medline].

  46. Pérez-Santonja JJ, Bellot J, Claramonte P, Ismail MM, Alió JL. Laser in situ keratomileusis to correct high myopia. J Cataract Refract Surg. 1997 Apr. 23(3):372-85. [Medline].

  47. Quillen DA, Rosenwasser GO. Aerosol application of cyanoacrylate adhesive. J Refract Corneal Surg. 1994 Mar-Apr. 10(2):149-50. [Medline].

  48. Refojo MF, Dohlman CH, Ahmad B, Carroll JM, Allen JC. Evaluation of adhesives for corneal surgery. Arch Ophthalmol. 1968 Nov. 80(5):645-56. [Medline].

  49. Rosenbery S. Corneal dellen following contact-lens wear. Am J Ophthalmol. 1969 Jun. 67(6):970. [Medline].

  50. Roy FH. Ocular Differential Diagnosis. 4th ed. Philadelphia: Lea and Febiger; 1984.

  51. Rubinfeld RS, Pfister RR, Stein RM, Foster CS, Martin NF, Stoleru S, et al. Serious complications of topical mitomycin-C after pterygium surgery. Ophthalmology. 1992 Nov. 99(11):1647-54. [Medline].

  52. Schwartz DE. Corneal sensitivity in diabetics. Arch Ophthalmol. 1974 Mar. 91(3):174-8. [Medline].

  53. Shivitz IA, Arrowsmith PN. Delayed keratitis after radial keratotomy. Arch Ophthalmol. 1986 Aug. 104(8):1153-5. [Medline].

  54. Smith RE, Schanzlin DJ. Rheumatoid diseases. Smolin, Thoft, eds. The Cornea: Scientific Foundations and Clinical Practice. 2nd ed. Boston: Little, Brown & Co; 1997.

  55. Smith SG, Lindstrom RL, Nelson JD, Weiss JL, Doughman DJ. Corneal ulcer-infiltrate associated with soft contact lens use following penetrating keratoplasty. Cornea. 1984. 3(2):131-4. [Medline].

  56. Soong HK, Quigley HA. Dellen associated with filtering blebs. Arch Ophthalmol. 1983 Mar. 101(3):385-7. [Medline].

  57. Stern GA, Weitzenkorn D, Valenti J. Adherence of Pseudomonas aeruginosa to the mouse cornea. Epithelial v stromal adherence. Arch Ophthalmol. 1982 Dec. 100(12):1956-8. [Medline].

  58. Swinger CA, Villasenor RA. Homoplastic keratomileusis for correction of myopia. J Refr Surg. 1985. 1:219-23.

  59. Townsend WM. Corneal melt after cataract surgery. Conjunctival flaps. The Cornea. New York: Churchill Livingstone; 1988. 669.

  60. Vitrectomy with silicone oil or perfluoropropane gas in eyes with severe proliferative vitreoretinopathy: results of a randomized clinical trial. Silicone Study Report 2. Arch Ophthalmol. 1992 Jun. 110(6):780-92. [Medline].

  61. Vitrectomy with silicone oil or sulfur hexafluoride gas in eyes with severe proliferative vitreoretinopathy: results of a randomized clinical trial. Silicone Study Report 1. Arch Ophthalmol. 1992 Jun. 110(6):770-9. [Medline].

  62. Waring GO 3rd, Lynn MJ, Gelender H, Laibson PR, Lindstrom RL, Myers WD, et al. Results of the prospective evaluation of radial keratotomy (PERK) study one year after surgery. Ophthalmology. 1985 Feb. 92(2):177-98, 307. [Medline].

  63. Weiss JL, Williams P, Lindstrom RL, Doughman DJ. The use of tissue adhesive in corneal perforations. Ophthalmology. 1983 Jun. 90(6):610-5. [Medline].

  64. Wilhelmus KR. Corneal edema following argon laser iridotomy. Ophthalmic Surg. 1992 Aug. 23(8):533-7. [Medline].

  65. Wilhelmus KR, Hamburg S. Bacterial keratitis following radial keratotomy. Cornea. 1983. 2:143-6.

  66. Zabel RW, MacDonald IM, Mintsioulis G. Corneal endothelial decompensation after argon laser iridotomy. Can J Ophthalmol. 1991 Dec. 26(7):367-73. [Medline].

All material on this website is protected by copyright, Copyright © 1994-2016 by WebMD LLC. This website also contains material copyrighted by 3rd parties.